1. (A) Urinary L-FABP (ULFABP) values in eight participants who had more than 5 µg/g creatinine (Cr) at the start of the study, at baseline and after treatment with anagliptin at 24 weeks. p<0.01 versus baseline. (B) Percentage change in UFABP (Δ%UFABP) in eig...
(A) Urinary L-FABP (ULFABP) values in eight participants who had more than 5 µg/g creatinine (Cr) at the start of the study, at baseline and after treatment with anagliptin at 24 weeks. p<0.01 versus baseline. (B) Percentage change in UFABP (Δ%UFABP) in eight participants from baseline to after treatment with anagliptin at 24 weeks. p<0.001 versus baseline. Error bars represent SD. L-FABP, liver-type  fatty acid-binding protein.
Munehiro Kitada et al. BMJ Open Diab Res Care 2017;5:e000391
©2017 by American Diabetes Association